Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. [electronic resource]
Producer: 20180108Description: 102-111 p. digitalISSN:- 1532-3064
- Administration, Inhalation
- Adrenal Cortex Hormones -- administration & dosage
- Adrenergic beta-2 Receptor Agonists -- administration & dosage
- Adult
- Asthma -- drug therapy
- Bronchodilator Agents -- therapeutic use
- Cholinergic Antagonists -- therapeutic use
- Double-Blind Method
- Drug Therapy, Combination
- Drug Tolerance -- physiology
- Female
- Forced Expiratory Volume -- drug effects
- Humans
- Male
- Middle Aged
- Nebulizers and Vaporizers -- standards
- Peak Expiratory Flow Rate -- drug effects
- Tiotropium Bromide -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.